BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 20676141)

  • 1. Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation.
    Yamaguchi H; Chen CT; Chou CK; Pal A; Bornmann W; Hortobagyi GN; Hung MC
    Oncogene; 2010 Oct; 29(41):5619-29. PubMed ID: 20676141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. c-Myc overexpression sensitizes Bim-mediated Bax activation for apoptosis induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through regulating Bcl-2/Bcl-xL expression.
    Jiang X; Tsang YH; Yu Q
    Int J Biochem Cell Biol; 2007; 39(5):1016-25. PubMed ID: 17331788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters.
    Xargay-Torrent S; López-Guerra M; Saborit-Villarroya I; Rosich L; Campo E; Roué G; Colomer D
    Clin Cancer Res; 2011 Jun; 17(12):3956-68. PubMed ID: 21652541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1.
    Chen S; Dai Y; Pei XY; Grant S
    Mol Cell Biol; 2009 Dec; 29(23):6149-69. PubMed ID: 19805519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis.
    Chen S; Zhang Y; Zhou L; Leng Y; Lin H; Kmieciak M; Pei XY; Jones R; Orlowski RZ; Dai Y; Grant S
    Blood; 2014 Oct; 124(17):2687-97. PubMed ID: 25208888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer.
    Stauber RH; Knauer SK; Habtemichael N; Bier C; Unruhe B; Weisheit S; Spange S; Nonnenmacher F; Fetz V; Ginter T; Reichardt S; Liebmann C; Schneider G; Krämer OH
    Oncotarget; 2012 Jan; 3(1):31-43. PubMed ID: 22289787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RhoB upregulation leads to either apoptosis or cytostasis through differential target selection.
    Marlow LA; Bok I; Smallridge RC; Copland JA
    Endocr Relat Cancer; 2015 Oct; 22(5):777-92. PubMed ID: 26206775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa.
    Inoue S; Riley J; Gant TW; Dyer MJ; Cohen GM
    Leukemia; 2007 Aug; 21(8):1773-82. PubMed ID: 17525724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.
    Nakagawa T; Takeuchi S; Yamada T; Ebi H; Sano T; Nanjo S; Ishikawa D; Sato M; Hasegawa Y; Sekido Y; Yano S
    Cancer Res; 2013 Apr; 73(8):2428-34. PubMed ID: 23382048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity.
    Thompson RC; Vardinogiannis I; Gilmore TD
    PLoS One; 2013; 8(5):e62822. PubMed ID: 23667527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
    Shao H; Gao C; Tang H; Zhang H; Roberts LR; Hylander BL; Repasky EA; Ma WW; Qiu J; Adjei AA; Dy GK; Yu C
    J Hepatol; 2012 Jan; 56(1):176-83. PubMed ID: 21835141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells.
    Barbetti V; Gozzini A; Cheloni G; Marzi I; Fabiani E; Santini V; Dello Sbarba P; Rovida E
    Epigenetics; 2013 Feb; 8(2):210-9. PubMed ID: 23321683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim.
    Zhao Y; Tan J; Zhuang L; Jiang X; Liu ET; Yu Q
    Proc Natl Acad Sci U S A; 2005 Nov; 102(44):16090-5. PubMed ID: 16243973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex.
    Piazza R; Magistroni V; Mogavero A; Andreoni F; Ambrogio C; Chiarle R; Mologni L; Bachmann PS; Lock RB; Collini P; Pelosi G; Gambacorti-Passerini C
    Neoplasia; 2013 May; 15(5):511-22. PubMed ID: 23633923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
    Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
    Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.
    Rahmani M; Aust MM; Benson EC; Wallace L; Friedberg J; Grant S
    Clin Cancer Res; 2014 Sep; 20(18):4849-60. PubMed ID: 25070836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shikonin induces apoptosis of lung cancer cells via activation of FOXO3a/EGR1/SIRT1 signaling antagonized by p300.
    Jeung YJ; Kim HG; Ahn J; Lee HJ; Lee SB; Won M; Jung CR; Im JY; Kim BK; Park SK; Son MJ; Chung KS
    Biochim Biophys Acta; 2016 Nov; 1863(11):2584-2593. PubMed ID: 27452907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitor potentiates chemotherapy-induced apoptosis through Bim upregulation in Burkitt's lymphoma cells.
    Dos Santos Ferreira AC; Fernandes RA; Kwee JK; Klumb CE
    J Cancer Res Clin Oncol; 2012 Feb; 138(2):317-25. PubMed ID: 22131152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells.
    Chen S; Zhao Y; Gou WF; Zhao S; Takano Y; Zheng HC
    PLoS One; 2013; 8(11):e79781. PubMed ID: 24236158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
    Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK
    Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.